Clinical trial
Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally…
NCT00004190 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00004190 |
|---|---|
| Title | Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer |
| Official title | A Phase I(Limited)/Phase II Study of Oxaliplatin (OXAL) and Gemcitabine (GEMZAR) in Patients With Metastatic Pancreatic Carcinoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, oxaliplatin |
| Enrollment | 59 |
| Start date | Oct 1, 1999 |
| Primary completion | Apr 1, 2003 |
| Completion | Jun 1, 2003 |
| First posted | May 25, 2004 |
| Last update posted | Jul 14, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: